Background: Biodegradable Temporising Matrix (BTM) has become an essential resource since its introduction to the market in 2016. (1) It is increasingly used for soft tissue reconstruction. We aimed to review the use of BTM at Waikato Hospital over a four-year period for the reconstruction of wounds secondary to necrotising soft tissue infections. Methods: A retrospective descriptive analysis was used to review patients who received BTM for necrotising infections. We reviewed the Waikato Hospital sterile stores consignment log of BTM issued from 1st January 2020 to 31st December 2023, and cross referenced to local discharge summaries. Results: 422 cases had BTM issued. 37 cases were excluded: 2 used no BTM, 1 for invalid data recorded, and 35 as duplicate entries. 21 (5.5%) of the 384 included patients over this period had BTM applied for necrotising soft tissue infections. Of these 9 (42.9%) were female, 13 (61.9%) were NZ European, 7 (33.3%) were Maori and there was an average age of 56 years (range 28-87). BTM was applied to the Upper Limb (6, 28.6%), Lower Limb (14, 66.7%) and the Trunk (1, 4.9%). 17 (81.0%) were subsequently skin grafted. 3 (14.3%) required a second application of BTM. Only 2 (9.5%) had the BTM removed, due to change of management with conversion to either limb amputation or free flap coverage. 20 had available microbiology results, 1 (5%) produced no culture growth, 7 (35%) had polymicrobial growth. The commonest isolate was Group A Streptococcus found in 6 cases (30%), and 1 (5%) case had fungal growth positive for Candida. Discussion: In this single centre case series, BTM demonstrates feasibility as a reconstructive option following necrotising soft tissue infection across our patient population.